Complementing Caregility virtual observation for ICUs, CLEW has launched the first FDA-cleared AI-powered predictive analytics platform in support of adult ICU patients.
In 2021, “CLEWICU,” CLEW’s AI-based ICU solution, received the FDA’s first clearance to predict hemodynamic instability in adult patients. It provides warning of clinical deterioration up to eight hours in advance, and also identifies low-risk patients who are unlikely to deteriorate, thus improving ICU resource allocation. This tool complements CLEW’s previously FDA-cleared solution, which predicts respiratory deterioration in COVID-19 and other ICU patients.
Visit CLEW to learn more.